Asset profile

HRS-7535

Small molecule

Phase 3underway

Evidence outlook · registrational

Hypertension: registrational readout pending

Its supporting mid-stage evidence has not yet been graded on this platform. Registrational readout expected around 2027-12.

Also in development:Type 2 Diabetes · Phase 3Obesity · Phase 3Heart Failure · Phase 2

How the evidence outlook works ↗

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov — registry estimates, never confirmed readout dates; they can move as trials progress.

2026 (1)
December 2026 (1)
Phase 2ObesityRecruiting
Est. primary completion 2026-12 · NCT06820099 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

2027 (2)
July 2027 (1)
Phase 2ObesityRecruiting
Est. primary completion 2027-07-07 · NCT07497880 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

December 2027 (1)
Phase 3HypertensionRecruiting
Est. primary completion 2027-12 · NCT07528027 · CT.gov ↗
What to watch

Research analysis

Source-grounded endpoint goals, benchmarks, comparator context, and caveats for this readout are included with Research.

See the full readout calendar ↗

All registered studies

Research

Unlock the complete ClinicalTrials.gov registry

Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.

Competitive landscape

Research

Unlock the competitor landscape

Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.